- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02081859
Use of Time-lapse Morphological Kinetics in the Selection of Blastocysts (Embryoscope)
Does Use of Time-lapse Morphological Kinetics in the Selection of Blastocysts for Transfer Improve Pregnancy Rates?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Materials and Methods:
Patient Selection:
Patients undergoing an IVF cycle at the Cleveland Clinic Reproductive Endocrinology and Infertility clinic with the plan for transfer of embryo(s) will be offered the opportunity to participate in this study. We would like a total enrollment 300 patients with 150 in each group. The only patients excluded will be those undergoing pre-implantation genetic testing and/or chromosome screening.
Study Design This will be a prospective randomized controlled trial where all patients who agree to participate will be randomized to having embryo selection for transfer based solely on conventional criteria or alternatively conventional criteria in conjunction with morphokinetic criteria.
Enrollment:
Patients will be enrolled at the Beachwood IVF center by the REI physicians at the time of the IVF consultation. They will sign the informed consent for the study at the time that they sign the consent for IVF treatment, which is done by the IVF nurses. Informed consent for the study will be kept in the patient chart in the Beachwood IVF center along with the IVF consent.
Randomization:
Patients will be randomized 1:1 to Conventional embryo selection vs. Embryoscope selection using a computer generated random number sequence. Group assignment will be written on a piece of paper and placed in consecutively numbered opaque envelopes by research personnel not involved in embryo selection. Each patient randomized will be assigned the next consecutive number and the embryo selection criteria will be revealed at time of oocyte retrieval. Patients, REI physicians and staff, and sonographers will be blinded as to how embryos are selected. Only the embryologist and the lab staff will be aware of which group the patients are randomized into. This will be ensured by not placing the group in the computerized medical record or the clinical chart, but only in the laboratory chart and the research database.
Sample Size Justification Little published data is available on time-lapse imaging and human embryo selection for transfer. No publications of randomized controlled trials are available on the EmbryoScope. Statistician Benjamin Nutter was consulted for sample size estimation. Initially, based on the 2012 outcomes there was a pregnancy rate of 49%. For a power of 80%, in order to detect an increase to 55% pregnancy rates under the new selection guidelines, we would need to randomize 1088 patients. To see an increase to 60% pregnancy rates, we would need to randomize 320 patients.
In this study, we will be focusing on those patients who have blastocysts available for transfer since blastocysts are the embryos that we need the most assistance with selection. The pregnancy rate in this subset of patients is currently 70% and to detect an increase to 80% would require randomization of 231 patients. Based on these numbers we feel it is reasonable to start with a goal of 300 patients in this study as there will be some patients that do not make it to retrieval, some that have no fertilization and some that have no embryos progress to transfer. Starting with a goal of 300 patients will hopefully give us a large enough sampling to do a preliminary analysis of embryos resulting in a clinically evident pregnancy as defined by positive fetal heart rate.
Given that the outcome of this study is pregnancy rate we will assess the data collected after six months to evaluate if there is a clear difference between groups. If there is a significant difference at that time, the study may be terminated to allow for all patients to have the benefit of the superior method.
Research Procedure The basic IVF laboratory protocols utilized will be the same as that used for all patients. Oocytes will be recovered by transvaginal aspiration of follicles under ultrasound guidance. Oocytes will be inseminated by intracytoplasmic sperm injection or co-incubation with sperm. The next morning, normally fertilized oocytes will be identified and moved to individual wells in a slide chamber and placed in the EmbryoScope.
Those randomized to classic evaluation will have their embryos graded based on conventional daily evaluation at specified daily time points. These criteria encompass timely development to specific benchmarks at 20, 26, 44, 68, 92, 116 and 140 hours post-insemination.
The images will be from the EmbryoScope, but will be static in time and will not span across a time range. Embryos will be graded and selected for transfer according to the laboratory's conventional criteria. Those randomized to classic evaluation plus morphokinetic parameters will have embryo evaluation performed at the same defined intervals but using the data analysis software and the captured time-lapse images to include timing of mitotic intervals, cleavage planes, timing of compaction and cavitation in embryos leading to blastocyst formation.
Patients electing not to participate in the study would still have their embryos cultured in the EmbryoScope and conventional embryo selection criteria would be applied to identify embryos fro transfer.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
- Cleveland Clinic Beachwood Family Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients undergoing an IVF cycle between the age of 18-45 at the Cleveland Clinic Reproductive Endocrinology and Infertility clinic with the plan for transfer of embryo(s) will be offered the opportunity to participate in this study.
Exclusion Criteria:
The only patients excluded will be those undergoing pre-implantation genetic testing and/or chromosome screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Conventional grading
Embryos will be scored based on conventional criteria.
|
|
|
Active Comparator: Embryoscope data
Embryos will be scored based on both conventional rating and embryoscope data.
|
The embryoscope is a microscope that allows for continuous time-lapse monitoring.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Pregnancy Rate
Time Frame: 6 weeks
|
Patients will have a ultrasound to document fetal heart rate approximately 6 weeks after start of IVF cycle.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implantation Rate
Time Frame: 6 weeks
|
Percent of embryos implanted assessed at time of ultrasound
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nina Desai, PhD, The Cleveland Clinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 14-090
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Viability
-
EugoniaCompleted
-
Cerus CorporationCompletedFocus: Assess Post Infusion Viability of S303 RBCsUnited States
-
Cairo UniversityCompletedAbdominal Wall Viability | Abdominal Wall Laxity | Abdominal LipodystrophyEgypt
-
Chelsea and Westminster NHS Foundation TrustUnknownDepression | Anxiety | Uncertain Viability of Pregnancy
-
National Taipei University of Nursing and Health...CompletedAnxiety | Uncertain Viability of PregnancyTaiwan
-
Klinički Bolnički Centar ZagrebRecruitingCABG | Myocardial ViabilityCroatia
-
University of Texas Southwestern Medical CenterAmerican Heart AssociationRecruitingCoronary Artery Disease | Myocardial Viability | Ischemic Heart Disease (IHD)United States
-
Cardio Med Medical CenterGeorge Emil Palade University of Medicine, Pharmacy, Sciences and Technology... and other collaboratorsCompletedAssessment of Lesion-Associated Myocardial Ischemia Based on Fusion Coronary CT Imaging (FUSE-HEART)Myocardial Ischemia | Coronary Stenosis | Myocardial Viability | Vulnerable Coronary PlaquesRomania
-
RWTH Aachen UniversityCompletedMyocardial Viability in Ischemic Left Ventricular Dysfunction | Prediction for Improvement in Cardiac Function After Revascularization TherapyGermany
-
Cardio Med Medical CenterUniversity of Targu Mures, Romania; Tîrgu Mureș Emergency Clinical County Hospital...CompletedMyocardial Fibrosis | Coronary Stenosis | Acute Myocardial Infarction | Myocardial Viability | Vulnerable Coronary PlaquesRomania
Clinical Trials on Conventional Criteria
-
Tanta UniversityNot yet recruitingUltrasonography | Chronic Obstructive Pulmonary Disease (COPD) | Mechanical Ventilation WeaningEgypt
-
Qatar UniversityHamad Medical CorporationNot yet recruitingPregnancy | Gestational Diabetes | Diagnosis
-
Xueqin YangRecruitingNSCLC | Targeted Therapy | EvaluationChina
-
Hospital Mutua de TerrassaUnknownGestational DiabetesSpain
-
Tianjin Huanhu HospitalCompletedImage Evaluation | Endovascular Thrombectomy | Fluid-attenuated Inversion Recovery Sequence Vascular Hyperintensity-diffusion-weighted Imaging Mismatch(FVH-DWI Mismatch)China
-
Peking University Third HospitalChinese University of Hong KongCompletedAmyotrophic Lateral SclerosisChina
-
Monash UniversityHospital Raja Permaisuri BainunActive, not recruitingAged | Polypharmacy | Inappropriate Prescribing | Deprescriptions | Potentially Inappropriate MedicationsMalaysia
-
Assiut UniversityNot yet recruitingMonitor Adverse Events
-
Ain Shams UniversityNot yet recruiting
-
Central Hospital, Nancy, FranceCompleted